CWM
XPH icon

Compass Wealth Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Compass Wealth Management’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
24,153
+6,446
+36% +$359K 0.32% 67
2025
Q4 		$992K Buy
+17,707
New +$918K 0.25% 70

Other funds holding XPH

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
KWM
Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $18.1B AUM 15% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Compass Wealth Management's XPH Position: Q1 2026 in Review

Compass Wealth Management increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 36% in Q1 2026, buying an estimated $359K and bringing the position to 24,153 shares worth $1.31M. The position accounts for 0.32% of the portfolio, ranked #67.

Compass Wealth Management first reported a position in XPH in Q4 2025 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.

  • Compass Wealth Management held 24,153 shares of State Street SPDR S&P Pharmaceuticals ETF worth $1.31M as of Q1 2026.
  • Compass Wealth Management bought 6,446 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $359K.
  • State Street SPDR S&P Pharmaceuticals ETF made up 0.32% of Compass Wealth Management's portfolio in Q1 2026, its #67 holding.
  • Compass Wealth Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2025 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.

Based on Compass Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.